SI 613

Drug Profile

SI 613

Alternative Names: Hyaluronic acid/non-steroidal anti-inflammatory drug; Hyaluronic acid/NSAID; Non-steroidal anti-inflammatory drug/hyaluronic acid; NSAID/hyaluronic acid; SI-613

Latest Information Update: 05 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Seikagaku Corporation
  • Class Antirheumatics; Drug conjugates; Glycosaminoglycans; Nonsteroidal anti-inflammatories
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Osteoarthritis

Most Recent Events

  • 16 Jun 2017 Phase-II clinical trials in Osteoarthritis in USA (Intra-articular)
  • 12 May 2017 Seikagaku Corporation and Ono Pharmaceutical agree to co-promote and co-develop SI 613 for Osteoarthritis
  • 03 Feb 2017 Phase-III clinical trials in Osteoarthritis in Japan (Intra-articular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top